Biology and therapy of urological cancer metastasis

Asian Journal of Urology, 2016, 3 (4): 167-169 doi:

Editorial

Biology and therapy of urological cancer metastasis

Edwin M. Posadas^a, David J. McConkey^b, Leland W. K. Chung^c

a Cedars-Sinai Medical Center, Los Angeles, CA, USA;
b Department of Urology, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA;
c Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Abstract
Related Citation (0)

Download:

HTML

PDF (1744KB)
Export: BibTeX | EndNote (RIS)

Abstract From the early roots of modern urology to today, genitourinary (GU) cancers have been an important part of the fields of urology and cancer biology. As medical science has advanced, newer clinical and basic viewpoints have impacted the thinking and practice in this important field. As such, GU oncology has been consistently seen as an area of rapid evolution both in biological understanding and clinical care. GU cancers continue to rise in incidence worldwide. Moreover, they represent a significant portion of cancer mortality in Asia and the western world. These facts have been met with some of the boldest and most important advances in cancer biology and therapy that have reshaped this field.

Published: 02 November 2016

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Edwin M. Posadas
	David J. McConkey
	Leland W. K. Chung

TRENDMD:

Cite this article:

Edwin M. Posadas,David J. McConkey,Leland W. K. Chung. Biology and therapy of urological cancer metastasis[J]. Asian Journal of Urology, 2016, 3(4): 167-169.

URL:

http://www.ajurology.com/EN/ OR http://www.ajurology.com/EN/Y2016/V3/I4/167

[1]	Luo J. Non-invasive actionable biomarkers for metastatic prostate cancer. Asian J Urol 2016;3:170-6.
[2]	Xu J, Qiu Y. Role of androgen receptor splice variants in prostate cancer metastasis. Asian J Urol 2016;3:177-84.
[3]	Armstrong CM, Gao AC. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian J Urol 2016;3:185-94.
[4]	Lin D, Wang X, Choi SYC, Ci X, Dong X, Wang Y. Immune phenotypes of prostate cancer cells:evidence of epithelial immune cell-like transition. Asian J Urol 2016;3:195-202.
[5]	Yun EJ, Lo UG, Hsieh JT. The evolving landscape of prostate cancer stem cell (PCSC):therapeutic implications and future challenges. Asian J Urol 2016;3:203-10.
[6]	Kobayashi T. Understanding the biology of urothelial cancer metastasis. Asian J Urol 2016;3:211-22.
[7]	Nghiem B, Zhang X, Lam HM, True L, Coleman I, Nelson PS. Mismatch repair enzyme expression in primary and castrate resistant prostate cancer. Asian J Urol 2016;3:223-8.
[8]	Hirata T, Park SC, Muldong M, Wu CN, Yamaguchi T, Strasner A. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. Asian J Urol 2016;3:229-39.
[9]	Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN. Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian J Urol 2016;3:240-53.
[10]	Cheng S, Chen JF, Lu YT, Chung LWK, Tseng HR, Posadas EM. Applications of circulating tumor cells for prostate cancer. Asian J Urol 2016;3:254-9.
[11]	McConkey DJ, Choi W, Ochoa A, Dinney CPN. Intrinsic subtypes and bladder cancer metastasis. Asian J Urol 2016;3:260-7.
[12]	Shao Z, Wang AZ, George DJ, Zhang T. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian J Urol 2016;3:268-77.
[13]	Gulley JL, Madan RA. Developing immunotherapy strategies in the treatment of prostate cancer. Asian J Urol 2016;3:278-85.
[14]	Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma:biology and implications for therapy. Asian J Urol 2016;3:286-92.